ArGEN-X
Note: This article was deleted from Wikipedia (no indication of notability). Retrieved from Wayback.
| Headquarters | , |
|---|---|
Key people |
|
| Revenue | 2,143,000,000 euro (2024) |
Net income | 792,700,000 euro (2024) |
| Website | argenx |
Argenx SE (Euronext: ARGX) is a Dutch biopharmaceutical company.
The company has been a member of the EURO STOXX 50 since 22 September 2025.
Products
In April 2025, the US FDA approved a prefilled syringe version of the company's immune disorder [...] Vyvgart.
Comments